Clinical Trials Logo

Filter by:
NCT ID: NCT03290729 Completed - Alveolar Bone Loss Clinical Trials

Wedge Implant Narrow Crests: Multi-center Clinical Study

Start date: May 15, 2017
Phase: N/A
Study type: Interventional

This study was designed as a multicentric prospective clinical trial to assess the clinical, biological and patient's perceived success of new wedge-shaped dental implants inserted in narrow ridges.

NCT ID: NCT03290521 Completed - Pain, Postoperative Clinical Trials

Intraperitoneal Lavage for Reducing Pain in Laparoscopy

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

The aim of the present study is to evaluate the role of intraperitoneal washing irrigation with saline solution at the end of laparoscopic hysterectomy or myomectomy in reducing perception of postoperative pain.

NCT ID: NCT03289273 Completed - Liver Neoplasms Clinical Trials

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Start date: September 13, 2017
Phase:
Study type: Observational

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

NCT ID: NCT03288844 Completed - Clinical trials for Limbal Stem Cell Deficiency Due to Ocular Burn

Follow-up Study After ACLSCT for Restoration of Corneal Epithelium in Patients With LSCD Due to Ocular Burns

HOLOCORE-FU
Start date: December 13, 2017
Phase:
Study type: Observational

This is a multinational, multicentre, prospective, non-pharmacological follow-up study of the clinical trial HOLOCORE. All patients transplanted with Holoclar in the HOLOCORE clinical trial who consent to participate will be enrolled in this prospective study and observed for at least 12 months.

NCT ID: NCT03288623 Completed - Physical Activity Clinical Trials

The Effects of Dark Chocolate Implementation in Elite Athletes

Start date: September 25, 2017
Phase: N/A
Study type: Interventional

Dark chocolate (DC) is rich in epicatechin which augments nitric oxide (NO) production through endothelium-dependent influences. The increased bioavailability and activity of NO have been demonstrated to statistically increase flow-mediated dilation in healthy subjects and in hypertensive patients. DC supplementation has been hailed for its positive effects on cardiovascular health and it has been proposed as a booster of physical performance in athletes, however the mechanisms by which DC improves oxidative stress, vascular function and athletic performance are not fully understood. The investigators designed a human study assessing how DC improves NO bioavailability and activity in elite athletes. Twenty-four elite soccer players (aged 18-35 years old, all males) are divided in 2 groups and randomly assigned to receive DC (85% cocoa), 40g per day or white/milk chocolate (<35% cocoa) for 30 days. The primary outcome measure is the evaluation of Soluble NOX2-derived peptide (sNOX2-dp), a direct marker of NADPH oxidase activation. The secondary outcome measures are other markers of oxidative stress, as the soluble P-selectin (sPs), Vitamin E, soluble CD40 Ligand (sCD40L), a marker of in vivo platelet activation and flow-mediated dilation assessed by vascular ultrasound. All parameters are assessed at baseline and after 30 days in both groups.

NCT ID: NCT03288155 Completed - Parkinson Disease Clinical Trials

Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

This study determines to evaluate the effectiveness of the daily consumption of flavonoid-rich cocoa in the treatment of fatigue in Parkinson's patients. The participants were divided equally between the flavonoid-rich cocoa (device) and control cocoa groups. The participant will engage in a six day trial, with measures taken at Day 1 and Day 6.

NCT ID: NCT03286894 Completed - Healthy Clinical Trials

AQUAPed: Validation Study of AQUA© Questionnaire Modified for Childhood

AQUAPed
Start date: September 1, 2017
Phase:
Study type: Observational

The AQUA© questionnaire developed in 2008 is a validated tools for the screening of allergic diseases in adult athletes. The objective of the present study is to develop and validate a modified version of the AQUA© questionnaire to be used in childhood. In this phase, the validation is intended to assess the reliability of the information collected through the AQUA© modified version: question difficulty and response patterns with respect to children characteristics (in particular age, sex and physical activity). In particular, the focus will be on the "core questions", i.e. the indicators of allergic disorders. This is a cross-sectional study on 1264 healthy schoolchildren aged 8 to 14 years.

NCT ID: NCT03286842 Completed - Clinical trials for HER2-ve Metastatic Breast Cancer

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Start date: January 17, 2018
Phase: Phase 3
Study type: Interventional

This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve metastatic breast cancer associated with germline or somatic breast cancer susceptibility gene (gBRCA1/2 or sBRCA1/2) mutations.

NCT ID: NCT03286400 Completed - Thoracic Diseases Clinical Trials

Observational Registry Characterizing the CTAG Device With ACTIVE CONTROL

SURPASS
Start date: October 18, 2017
Phase:
Study type: Observational [Patient Registry]

Collect real-world clinical and device-specific outcomes of the GORE® TAG® Conformable Thoracic Stent Graft featuring ACTIVE CONTROL System (CTAG Device with ACTIVE CONTROL) in the treatment of aortic disease as part of routine clinical practice.

NCT ID: NCT03286049 Completed - Rhinitis Clinical Trials

Short and Mid-term Repeatability of Active Anterior Rhinomanometry (AAR) Measurements in Paediatric Age

Rhino-Rep
Start date: January 10, 2018
Phase:
Study type: Observational

Longitudinal, observational study to assess the short-term (test re-test) and mid-term (within the span of 28 days) repeatability of active anterior rhinomanometry (AAR) measures on 4 parallel groups of children with different rhinitis phenotypes, and 1 group of control (healthy) children. Secondary objectives are: i) assessing of association between AAR, exhaled FeNO (eFeNO) and nasal FeNO (nFeNO); ii) assessing association between objective measurements (AAR, eFeNO and nFeNO) and subjective measurements (Total 5 Symptom score, T5SS). The study is intended to obtain useful information for improving rhinitis management.